Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4464 in advanced/metastatic solid tumors
NCT05514444Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2022
- Primary completion
- Sep 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, T-cell Engagers
- Countries
- 4
01
Overview
Phase 1, open-label trial of MK-4464 in solid tumor (3 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events at 27 months and 1 more. Started Sep 2022; status: completed.
02
Drugs
MK-4464
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05514444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05514444.